MAP2K5(MEK5)
Sign in to save this workspaceUniProt Q13163 · PDB · AlphaFold · Substrate: ERK5 (K84R) · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Nintedanib | 98.6% | 1.4% | 90.23 | 0.608 |
| 2 | Ponatinib | 96.7% | 3.3% | 78.23 | 0.534 |
| 3 | Dasatinib | 96.2% | 3.8% | 87.97 | 0.699 |
| 4 | Vemurafenib | 94.4% | 5.6% | 96.49 | 0.598 |
| 5 | Dabrafenib | 88.7% | 11.3% | 94.74 | 0.633 |
| 6 | Canertinib | 73.2% | 26.8% | 96.49 | 0.671 |
| 7 | Erlotinib | 70.9% | 29.1% | 99.75 | 0.695 |
| 8 | Avapritinib | 54.9% | 45.1% | 97.73 | 0.644 |
| 9 | Rabusertib | 53.9% | 46.1% | 98.74 | 0.687 |
| 10 | Gefitinib | 48.5% | 51.5% | 99.25 | 0.650 |
| 11 | Osimertinib | 46.8% | 53.2% | 97.24 | 0.733 |
| 12 | Regorafenib | 44.8% | 55.2% | 95.99 | 0.719 |
| 13 | Dacomitinib | 36.2% | 63.8% | 97.99 | 0.664 |
| 14 | Ripretinib | 36.2% | 63.8% | 92.95 | 0.674 |
| 15 | Crizotinib | 34.1% | 65.9% | 91.39 | 0.581 |
| 16 | Brigatinib | 28.2% | 71.8% | 82.96 | 0.513 |
| 17 | Darovasertib | 26.8% | 73.2% | 96.99 | 0.719 |
| 18 | Ceritinib | 20.3% | 79.7% | 95.44 | 0.618 |
| 19 | Ibrutinib | 18.7% | 81.3% | 94.74 | 0.723 |
| 20 | Sorafenib | 17.1% | 82.9% | 96.72 | 0.776 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.43
- Epithelial log2(TPM+1): 3.36
- Fold change: 0.07
- Status: No significant change
Selectivity landscape vs inhibition on MAP2K5
Each point is one of the 92 approved drugs; color = inhibition % on MAP2K5.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…